Earlier trials randomized to donepezil 5 mg/day, donepezil 10 mg/day, and placebo revealed cognitive benefits in patients with AD receiving higher dose of donepezil (10 mg/day) regardless of the stages, and even higher dose could bring further benefit considering there is still room for suppressing cholinesterase activity to the maximum. The gene discussed is BCHE; the disease is Alzheimer disease.